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842-2 Accumulation of a Novel Macrophage-Targeting 
Photodynamic Compound Within Lipid-Rich 
Atherosclerotic Plaques 
Ahmed Tawekol, Alan Fischman, Tayyaba Hasan, Touqir Zahra, James Muller, Michael 
Hamblin, Massachusetts General Hospital, Boston, Massachusetts. 
Vulnerable atherosclerotic plaques contain an abundance of inflammatory cells. We 
recently developed a photodynamic therapeutic (PDT) agent, (chlorin e8 conjugated with 
maleylatad albumin), that is recognized by scavenger receptors and can target macroph- 
ages with high selectivity. We therefore sought to test the hypothesis that the novel mac- 
rophage-targeting photodynamic compound accumulates in experimental atherosclerotic 
lesions in quantities that are sufficient for photodynamic therapy. 
Four New Zealand rabbits were studied, in which atherosclerotic lesions were induced in 
2 by de-endothelialization of the infradiaphragmatic aorta followed by a 6% peanut oil-2% 
cholesterol diet for 10 weeks. Thereafter chlorine6 conjugated with maleylated albumin 
was administered intravenously to the animals. At 24 hours after injection of the PDT 
compound, the animals were sacrificed, and the aortas examined for uptake of the fluo- 
rescent PDT agent. 
PDT uptake was significantly higher within the atherosclerotic aortas (5.2 +/- 3.2 vs. 1.9 
+/- 1.2, ca6 fluorescence units/gm tissue x 10 6 atherosclerotic aorta vs control aorta, 
p<0.03, n=8 segments). 
These data indicate that this macrophage-targeted photodynamic ompound accumu- 
lates in atherosclerotic plaques, and support future efforts to employ PDT compounds to 
ablate inflammatory foci within atherosclerotic plaques. 
9:00 a.m. 
842-3 Stat in Admin is t ra t ion  in Pat ients  With Acute  Coronary  
Syndromes: Results in Decreased Heat Release of  
Culprit Atherosclerotic Lesions 
Christodoulos Stefanadis. Konstantinos Toutouzas, Elefthedos Tsiamis, Ioannis 
Kallikazaros, Manolis Vavouranakis, Sophia Vaina, Athanasios Trikas, Christina 
Chrysochoou, Dimos Panagiotakos, PavIos Toutouzas, Hippokration Hospital, Athens, 
Greece. 
Background: It has been shown, that there is thermal heterogeneity within human ath- 
eroscterotic plaques. Recent studies have suggested, that statins may induce mechani- 
cal plaque stability by reduction of inflammatory cells within the plaque. This study was 
designed to examine the effect of statins on atherosclerotic plaque stabilization by mea- 
suring the temperature of atherosclerotic plaques. Methods: We studied 60 patients 
(pts), 36 pts with unstable angina (UA) and 24 pts with acute myocardial infarction (AMI). 
All pts underwent diagnostic catheterization. Thirty-two pts (18 pts with UA and 14 pts 
with AMI) were under statin treatment for over a month and 28 pts were not receiving 
statins (18 pts with UA and 10 pts with AMI). Fifty-five pts were under aspirin treatment. 
Total cholesterol and low-density cholesterol were measured in all pts. A thermography 
catheter previously validated (Medispes S.W.A.G.zug-Switzerland) was used during the 
diagnostic catheterization, in order to measure the temperature difference (TD) between 
the atherosclerotic plaque and the healthy vessel wall. Results: TD was progressively 
increased in pts with UA compared to pts with AMI (0.41 ± 0.28 vs 0.68 ± 0.41°C, p < 
0.02). When we categorized the study population into pts receiving statins and pts not 
treated with statins, TD was lower in the treated group (0.41 ± 0.4 vs 0.85 ± 0.3°C, p < 
0.01). Moreover, untreated pts with UA or AMI had greater TD compared to treated pts 
(UA: 0.45 ± 0.26 vs 0.29 ± 0.25°C, p < 0.02; AMI: 0.82 ± 0.51 vs 0.56 ± 0.34 ° C, p < 
0.01). Multivariate analysis showed that treatment with statins was an independent factor 
in the assessment of temperature variation, adjusted for age, hypercholesterolemia, 
hypertension, smoking, aspirin intake, and clinical syodrome.Conclusions: Pts with 
unstable plaques, under stalin tretment have decreased heat production from the culprit 
lesion Thus, statins may exert a direct antinflammatory effect in the atherosclerotic 
plaque beyond their effects on plasma lipids. 
9:15 a.m. 
842-4 Association Between Ischemic Electrocardiographic 
Abnormalities and C-Reactive Protein in a General 
Population 
Folkert W. Asselberos, Ad J. van Boven, Gilles F. Diercks, Hans H. Hillege, Erik M. 
Stuveling, Jan A. Kors, Wiek H. van Gilst, University of Groningen, Groningen, The 
Netherlands, Academic Hospital Groningen, Groningen, The Netherlands. 
Background: The inflammatory marker C-Reactive protein (CRP) and ischemic electro- 
cardiographic (ECG) abnormalities reflects both vascular instability and are easy to 
obtain risk factors for fatal and nonfatal cardiac events. Their association however, has 
never been studied in a general population. Our objective was to test the hypothesis that 
there is an association between the level of CRP and the presence of electrocardio- 
graphic abnormalities. 
Methods: Minnesota coded electrocardiograms were used to determine ischemic elec- 
trocardiographic abnormalities in 8501 subjects (aged 28 to 75, 49.8% male) from the 
PREVEND study, a population-based screenings programme in which subjects were 
stratified for the presence of an increased level of urinary albumin excretion. High sensi- 
tive CRP was measured by nephelometry (BN II, Dade Behring, Marburg, Germany). 
Abnormal T-axis was defined as -180 to -15 and 105 to 180 degrees. CRP levels were 
divided below and above the upper quartile (CRP>2.60 mg/dl). 
Prevalence of ECG abnormalities, Odds Ratio (95% CI) 
Ischemic Infarct patterns Abnormal T-axis 
abnormalities 
Elevated CRP 1 1.56 (1.30-1.87)* 1.71 (1.32-2.22)* 3.18 (2,12-4.77)* 
Elevated CRP 2 1.39 (1.15-1.67)* 1.58 (1.21-2.01)* 2.64 (1.75-3.99)* 
Elevated CRP 3 1.24 (0.99-1.55) 1.34 (0.97-1.85) 2.18 (1.27-3.76)** 
*p<0.001 ,**p<0.01 
1 unadjusted 
2adjustad for age and gender 
3adjusted for age,geoder, hypercholestarelemia,diabetes, moking,family history for 
atherosclerose and body mass index>27kg/m2 
Conclusion: These results suggest that in a large general population, elevated CRP is 
associated with ECG abnormalities, suggestive for cardiac ischemia. Therefore, CRP may 
be useful in early risk profiling to improve cardiovascular isk assessment and treatment. 
9:30 a.m. 
842-5 Does Extent of Pretreatment Atherosclerosis Influence 
the Effects of Conjugated Equine Estrogens on 
Atherosclerosis Progression? 
Mary S. Anthony. Thomas B. Clarkson, Wake Forest University School of Medicine, 
Winston-Salem, North Carolina. 
Background: Recent clinical trial data suggest no beneficial effects of hormone replace- 
ment therapy (HRT) on coronary artery atherosclerosis progression in women with angio- 
graphically verified lumen stenosis. However, considerable observational and nonhuman 
primate data indicate that HRT inhibits progression of atherosclerosis in its early stages. 
Consequently, whether HRT has a differential effect on atherosclerosis progression 
depending on extent of preexisting atherosclerosis becomes importanL 
Methods: Cynomolgus monkeys were fed a moderately atherogenic diet for two years to 
induce atherosclerosis, after which a biopsy of the iliac artery was taken to quantify pre- 
treatment atherosclerosis (measured as intimal area [IA] averaged across three sections) 
and all animals were ovariectomized to induce surgical menopause. For the 3-yasr post- 
menopausal pedod, they were randomized to no treatment (Control, n=56) or conjugated 
equine estrogens (CEE, n=62) at a dose comparable to a dose for women of 0.825 rag/day 
and the atherogenic diet was continued. At the end of the study atherosclerosis was quan- 
tified in the contralataral lilac artery. For this analysis, individuals were divided into tertiles 
based on baseline IA. 
Results: Overall the CEE group had less atherosclerosis than the control group (p=0.002). 
As expected, IA at the end of the study was higher in the tertiles with more atherosclerosis 
at baseline (p for treod--O.0001). There were different effects of CEE depending on the 
amount of preexisting atherosclerosis (significant reatment by tertile interaction [p=0.01]). 
The nature of this interaction was that with increasing baseline atherosclerosis, there was 
less of a difference between the CEE and Control groups in outcome atherosclerosis, in 
the lowest tertile, IA at outcome was 0.30 mm 2 smaller in the CEE group compared to Con- 
trols (p=0.0001); in the middle tertile the CEE group IA was 0.15 mm 2 smalier (p=0.33) and 
in the highest terti~e IA was only 0.09 mm 2 smaller (p=0.71) in the CEE group. 
Conclusions: These data suggest that CEE might be less effective at inhibiting athero- 
sclerosis progression when pretreatment atherosclerosis is more advanced. 
9:45 a.m. 
842-6 PPAR ~hAgoniet Induces Regression of Atherosclerotic 
Plaques: In Vivo Study by High Resolution Magnetic 
Resonance Imaging 
Roberto CortL Julio L Osende, Valentin Fustsr, Samuel D. Wright*, Zahi A. Fayad, Elisha 
Dickstain, John T. Fallon, Juan J. Badimon, Cardiovascular Institute Mount Sinai School 
of Medicine, New York, New York, *Merck Research Laboratories, New Jerse~ 
Introduction Nuclear receptor PPAR- 7 regulates adipogenasis and lipid metabolism. It is 
expressed in macrophages and may have antiatherogenic effects. We reported the abil- 
ity of MRI to monitor in vivo changes in atherosclerotic (AT) lesions. Our objective was to 
compare the effects of simvsstatin, a PPAR~-agonist (2-(2-(4-phenoxy-2-propy- 
Iphoxy)ethyl)indole-5-acetic acid) and their combination on pre-established lesions in a 
rabbit model using MRI and histology. 
Methods Aortic AT lesions were induced in rabbits by double balloon-injury and athero- 
genic diet. Following lesion induction,animals were MRimaged and, based on severity of 
the established AT lesion, assigned to the different groups: Progression (no therapy, 
n=5), simvastatin (5mg/kg/day, n=6), PPAR~agonist (5mg/Kg/day, n=5) and their combi- 
nation (n=7). The atherogenic diet was maintained during the study. After 6 months of 
treatment all rabbits were MR imaged, sacrificed and processed for histology. The effect 
of the treatments on AT lesions was assessed by measuring vessel wall area (VWA), a 
surrogate of AT burden. VWA measurements by MRI were normalized to the randomiza- 
tion value (each rabbit served as its own control). 
Results Good agreement between MRI and histopatology measurements of VWA was 
found(p<0.001, R=0.88). The mean VWA at the time of randomization was 8.4±0,6 mm2 
and did not differ between groups. The progression group showed a significant increase 
(21%; p<0.01) in VWA. All treatments significantly regressed the established AT lesions. 
The major therapeutic effect was observed in the simvastatin+PPAR y group with a 14% 
reduction, while the simvaststin and the PPAR 7 groups had a 9.5% and 5% inhibition 
respectively.The composition and characteristics of the plaques are being analysed. 
Conclusion MRI documents serial changes in AT lesions in response to therapeutic 
interventions. We report striking effects on AT lesion regression by combining two mech- 
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8:45 a.m. 
843FO-2 Relation of Myocardial Fibrosis to Circu lat ing 
Aldosterone and Endothelin in Primary and Secondary 
Human Hypertension: An Ultrasonic Study by Acoustic 
Densitometry 
Micheela Kozakova, Simona Buralli, Carlo Palombo, Angelica Moretti, Giampaolo 
Bernini, isabella Sudano, Stefano Taddei, Antonio Salvetti, Department of Internal 
Medicine, University Medical School, Pisa, Italy, CNR Institute of Clinical Physiology, 
Pisa, Italy. 
Myocardial fibrosis is found in the expadmental hypertensive heart and may be a major 
cause of heart failure in man. In experimental models, EndotheUn and Aldosterone were 
shown to act synergically in promoting myocardial fibrosis. 
Aim of the study was to investigate the possible relations between myocardial fibrosis as 
assessed by an advanced ultrasound technique (Acoustic Densitometry, AD, Agilent Tech- 
nologies), and circulating levels of Endothelin and Aldostsrone in pnmary and secondary 
hypertension. 
Methods: 32 patients (21 males; mean age 50±11; BP 159±9/101±7 mmHg), including 15 
with essential hypertension (EH), 7 with unilateral rano-vascular disease (RVH), 10 with pd- 
mary aldostaronism (PA), were studied, plasma Aldosterone (Aldo), Endothelin (Endo), 
Renin activity, and Hydroxyprolinuda were measured and related to LV mass and function 
(M-mode echo), as well as to the average myocardial Integrated Backscatter (IBS; riB), 
obtained by AD as an estimate of myocardial fibrosis. 
Results: All subjects had preserved LV systolic function. In PA and RVH patients, IBS and 
Aldo were higher (p<0.01) than in EH (IBS: 25±5 and 24±7 vs 18±4 dB; Aldo: 1.19¢0.7, 
1.18±0.5 and 0.64¢0.2 nmol/L), while Endo was increased only in PA (4.3¢-0.7 pg/ml vs 
3.7±0.7 and 3.1±0.8 in RVH and EH, p<0.01), In the overall population, IBS correlated 
directly to Aldo (r=0.41, p<0.02), Endo (r=0.57, p<0.01), Hydroxyprolinuda (r=0.47, p<0.01), 
LV mass (r=0.54, p<0.0f), disease duration (r--0.35, p<0.05). In multivariate analysis, Endo, 
Hydroxyprolinuda, LV mass and disease duration were independently related to IBS 
(adjusted R2=0.87, p<0.01 for all). LV mass was directly related to hydroxyprolinuda (r--0.51, 
p<0.01), but not to hormonal factors. Endo was directly related to LV end-diastolic diameter 
(r=0.37, p<0.05) and showed a trend to increase with increasing Aldo (R---0.32, p=0.07). 
Conclusions: in human hypertension, myocardial fibrosis partakes of the hypertrophic pro- 
cess, is related to disease duration and dependent on a synergic interaction of Endo and 
Aldo. The clinical models of pdmary and secondary hyperaldosteronism seem more prone to 
such a development han essential hypertension. 
9:00 a.m. 
843FO-3 Rofecoxib but Not Celecoxib Increases Systolic Blood 
Pressure in Hypertensive Patients Treated With Ace 
Inhibitors and Beta-Blockers 
William B. White, Andrew Wheiton, John G. Fort, University of Connecticut School of 
Medicine, Farmington, Connecticut, Johns Hopkins Universi~ Baltimore, Maryland. 
Background: The effects of celecoxib 200 mg/d and rofecoxib 25 mg/d on BP control were 
assessed in a randomized, double-blind study in elderly patients with osteoarthdtis on sta- 
ble (>3 months) antihypertensive therapy. 
Methods: 1092 patients received celecoxib (n=549) or rofecoxib (n=543) with their antihy- 
pertensive regimen for 6 weeks. Primary endpoints were changes in systolic and diastolic 
BP. Changes from baseline in SBP by type of antihypertensive therapy were analyzed 
using laast-square means based on baseline score, gender, race, and treatment. 
Results: Mean age was 73.2 yrs; 62% were women. There were no significant changes 
from baseline in mean SBP in the celecoxib arm for patients on any therapy. Significant 
increases in SBP were observed in the rofecoxib group when treated with ACEI, 13-block- 
ers, or these agents in combination with a diuretic (P<0.05). There were no changes from 
baseline in mean DBP in either COX-2 inhibitor arm. Calcium antagonists and diuretics had 
less interaction with either COX-2 specific inhibitor. Mean changes in SBP (mmHg) are 
shown: 
Antihypertensivetherapy by Mean change (SD), Adjusted LS Mean Pvalue 
class mm Hg Difference [95% el] 
Celecoxib Rofecoxib 
ACEi (n=161) -0.4 (12.7) 4.9 (13.3) -3.9 [-6.2 to -1.6] <0.001 
ACEI/dluretic (n=82) -1.0 (11.1) 2.8 (15.3) -3.1 [-6.1 to -0.1] 0.04 
B-Blocker (n=106) 1.1 (12.8) 4.9 (13.0) -2.9 [-5.7 to -0,2] 0.04 
8-Blockerldluretio (n=78) -1.2 (11.0) 4.9(14.3) -4.8 [-7.9 to -1.7] 0.003 
Calcium antagonist (n=114) 0.4 (11.4) 9.1 (11.6) 0.2 [-2.0 to 2.4] 0.87 
Cslclumantagoniet/dluretic -1.1 (10.2) 0.1 (12.8) -1.2[-4.0to1.5] 0.4 
(n=65) 
Conclusions: Data demonstrate that rofecoxib attenuates SBP control in patients on 
ACEI, 8-blocker alone and in combination with a diuretic but not on the calcium antago- 
nists. Furthermore, cetecoxib does not attenuate BP control in patients on any class of anti- 
hypertensive drugs. 
9:15 a.m. 
843FO-4  Eplerenone Reduces Proteinuria in Type II D iabetes 
Mellitus: Implications for Aldoaterone Involvement in 
the Pathogenesis of Renal Dysfunction 
Murrav Eostein, Vardaman Buckalew, Jorge Altamirano, Barbara Roniker, Scott Krause, 
Jay Kleiman, University of Miami School of Medicine, Miami, Flodda, Wake Forest 
University School of Medicine, Winston-Salem, North Carolina. 
Background: Aldosteronc may promote renal dysfunction. We investigated whether the 
selective aldosterone receptor antagonist (SARA) eplerenone reduces proteinuria in 
hypertensive patients with type II diabetes mellitus and albuminuria. 
Methods: After 2-4 wk on placebo, patients were randomized to foroed-titrated oses of 
eplerenone (Epl), enalapdl (Enl), or Epl and Enl in combination (Comb) for 24 wk. If DBP 
was >90 mm Hg at _> 8 wk, hydrochlorothiazide or amlodipine was added to control BP. 
The primary endpoint was the mean % change in urinary albumin to creatinine ratio 
(UACR) at 24 wk. Secondary endpoints were blood pressure (BP) changes and tolerabil- 
ity. 
Results: Epl reduced UACR by 62% vs 45% with Enl (p=0.015), and Comb was more 
effective (74%, p=0.018 vs Epl and p<0.001 vs Enl), BP decreases were not different 
between Epl and Enl (Table). Both drugs were well tolerated. No gynecomastia was 
reported. Incidence of K + _>6.0 mEq/L was Epl (8), Enl (2), and Comb (8). More patients 
were withdrawn because of sustained hyperkalemia in the Comb group (14) than in Epl 
(6) or Enl (2) groups. Other adverse events were similar among treatment groups. 
Conclusion: Differences in protainuria reduction despite similar BP Iowedng indicate 
that renal protection is independent of blood pressure reduction, consistent with the 
hypothesis that selective aldosterone antagonism is renoprotective. Further investigation 
will determine whether lower Epl doses reduce proteinuda with fewer K ÷ changes in dia- 
betic patients. 
Epl Enl Comb En110 mg/ 
(50 up to 200 mg) (10 up to 40 mg) Epl (50 up to 200 rag) 
(N=74) (N=74) (N=67) 
UACR (mg/g) at Baseline 611.4 483.3 470.9 
UACR at 24 wk 248.8 285.3 120.8 
BP at 24 wk (SBP/DBP) -19.5/-13.2* -20.4/-15.0 -21.8/-16.2 
(N=89) (N=83) (N=85) 
*p=0.015 vs Comb 
9:30 a.m. 
843FO-5 Effect of  Valsartan on Morbidity and Morta l i ty  in Heart  
Failure Patients With a History of Hypertension: Results 
From the Valsartan Heart Fai lure Trial 
N. J, Holwerda. Lionel Opie, Nancy Feliciano, Janet Bodner, on behalf of the VaI-HaFT 
Investigators, Sint Elisabeth Zeikechuis, Tilburg, The Netherlands. 
Background: Patients with hypertension commonly progress to heart failure (HF) 
despite treatment with currently recommended drugs. In the Valsartan Heart Failure Tdal 
(VaI-HeFT), morbidity risk was significantly reduced by 13.2% with valsartan (40-160 mg 
bid) compared to placebo (p=O,009), with similar all-cause mortality risk in the two 
groups. Risk for time to first HF hospitalization (with mortality censoring) was significantly 
reduced by 27.5% with valsartan (p<0,001), In the post-hoc analysis of VaI-HeFT 
patients, the effect of valsartan compared to placebo on outcomes in patients with a his- 
tory of hypertension (HTN) was investigated, 
Methods: VaI-HeFT was an international, multicenter, randomized, double blind trial in 
5010 patients with New York Heart Association (NYHA) class II-IV HF. History of HTN 
was defined as: pre-randomization systolic blood pressure (BP) _>140 mmHg or diastolic 
BP _>90, reported past medical history of HTN, or HTN reported as the primary etiology of 
HF. The primary efficacy outcomes were time to death and time to first morbid event 
(death, sudden death with resuscitation, hospitalization for HF, intravenous inotropic or 
vasodilator therapy >4 hours]. A secondary efficacy outcome was time to first HF hospi- 
talization. 
Results: A subgroup of 2372 patients had a documented history of HTN at baseline, 
1143 of whom were randomized to receive valsartan and 1229 to placebo. The effects of 
valsartan on morbidity and mortality in HF patients with (HTN+) and without (HTN-) a his- 
tory of HTN were generally consistent with the overall study population. The risk ratio 
(RR) of all-cause mortality for valsartan vs. placebo was 0.99 (95% CI 0.83, 1.18) in 
HTN+ and 1.05 (95% CI 0.88, 1.25) in HTN- patients. Risk of morbidity was lower for val- 
cartan than placebo in HTN+ (RR = 0.88, 95% CI 0.77, 1.02) and HTN- patients (RR = 
0.85, 95% CI 0.74, 0.99). The results were similar for the risk of first hospitalization for 
HF in HTN+ (RR = 0.76, 95% CI 0.83 - 0.93) and HTN- patients (RR = 0.69, 95% CI 0.57, 
0.84). 
Conclusion: Valcartan treatment has beneficial effects in the treatment of HF when 
added to prescdbed therapy in HF patients with or without a history of hypertension. 
artistically distinct therapeutic agents, simvastatin and PPART-agonist. The effects of the 
hypolipidemic simvastatin, confirm the sensitivity of MRI measurements, and the effects 
of the PPAR~agonist suggest a novel class of antiartedosclerotic ompounds. 
